This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Heart Failure Obesity 
Cardiovascular Diabetology
SEPTEMBER 15, 2024
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. During the 4.22-year
98 
Cardiovascular Diabetology
FEBRUARY 11, 2024
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.
111 
American College of Cardiology
APRIL 6, 2024
The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).
Science Daily - Heart Disease
JUNE 23, 2024
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
102 
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.
American College of Cardiology
JANUARY 8, 2024
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
70 
Open Heart
MAY 23, 2024
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.
American College of Cardiology
JANUARY 15, 2025
Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
Cardiovascular Diabetology
MARCH 21, 2025
Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.
Cardiovascular Diabetology
MARCH 25, 2025
Heart failure (HF) is increasingly recognized as a heterogeneous cardiometabolic disorder, often in the context of overweight/obesity independently from diabetes. Sodium-glucose cotransporter-2 inhibitors (SGL.
American College of Cardiology
JUNE 24, 2024
Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
The British Journal of Cardiology
OCTOBER 8, 2024
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.
40 
Frontiers in Cardiovascular Medicine
DECEMBER 17, 2023
These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 trillion by 2050, according to two American Heart Association ( AHA ) presidential advisories published June 4 in the AHA journal Circulation.
105 
Journal of the American Heart Association
DECEMBER 29, 2023
AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.
45 
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2 of placebo-takers.
64 Stroke Journal
JANUARY 30, 2025
Background:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus (T2DM). Similarly, the risk of serious adverse events such as cerebrovascular accident (OR, 0.75(95%CI: 1.00),P=0.05), hemorrhagic stroke (OR, 0.82(95%CI:
Circulation: Heart Failure
JANUARY 28, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001). ms (36.4106.4;P=0.028)
Circulation
JUNE 4, 2024
Diabetes (16.3% to 26.8%) and obesity (43.1% to 9.2%), heart failure (2.7% We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% in 2020 to 61.0%
81 
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2024
Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health.
69 
HeartRhythm
MARCH 12, 2024
Diabetes mellitus (DM) is a public health problem that continues to grow worldwide. 2 As noted elsewhere,3 DM and AF affect a population that shares concomitant conditions such as obesity, hypertension and even heart failure (HF). of the population.1 of the population.1 Further, DM is a major risk for AF.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
All About Cardiovascular System and Disorders
FEBRUARY 27, 2024
They have a greater prevalence of obesity, dyslipidemia, metabolic syndrome and diabetes mellitus. Higher risk of myocardial infarction, heart failure and atrial fibrillation was noted in spinal cord injury survivors compared to controls. Survivors with severe disability had the highest risk. Am J Phys Med Rehabil.
Nature Reviews - Cardiology
MAY 27, 2024
Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01042-w In patients with type 2 diabetes mellitus and obesity, bariatric metabolic surgery is associated with a lower risk of the incidence of first-ever congestive heart failure than treatment with glucagon-like peptide 1 receptor agonists, according to a new study.
43 
Journal of Cardiovascular Pharmacology
JUNE 24, 2024
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.
DAIC
FEBRUARY 29, 2024
12:15 p.m.
103 Journal of the American Heart Association
FEBRUARY 26, 2025
Multimorbidity was defined as 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire.
European Journal of Heart Failure
MARCH 19, 2025
Semaglutide reduces late sodium current (I Na ) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end-stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. However, the exact mechanisms underlying its cardioprotective actions remain unclear.
Journal of the American Heart Association
MARCH 18, 2024
Changes in BCAA homeostasis have emerged as pivotal contributors in the pathophysiology of several cardiometabolic diseases, including type 2 diabetes, obesity, hypertension, atherosclerotic cardiovascular disease, and heart failure.
40 
Wellnest
FEBRUARY 28, 2023
Insufficient or interrupted sleep can affect blood pressure and increase the risk of heart attacks, stroke, diabetes, and other cardiovascular diseases. High blood pressure and heart disease are related to insomnia. Sleep Issues Are Caused by Heart Failure Heart failure complications may impact your sleep.
Journal of the American Heart Association
MARCH 19, 2025
The end point was the development of cardiotoxicity (defined as clinical heart failure or drop in left ventricular ejection fraction 10% to 50%).ResultsA Hypertension, diabetes, hyperlipidemia, obesity, and low socioeconomic status were more common in NH Black and Hispanic individuals. NonHispanic [NH] White, 30.5%
40 
ADN Center of Excellence
SEPTEMBER 2, 2024
AFib is associated with a fivefold increased risk of stroke, and it is also linked to heart failure, chronic fatigue, and other serious health issues. Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase.
59 
DAIC
DECEMBER 19, 2023
The device is a patented 3-lead, 2-channel wireless continuous ECG wearable device that allows physicians the ability to address and assess sleep and heart health remotely. Undiagnosed and untreated sleep apnea increases the risk of costly health complications like heart disease, hypertension, diabetes, and depression.
ADN Center of Excellence
SEPTEMBER 2, 2024
AFib is associated with a fivefold increased risk of stroke, and it is also linked to heart failure, chronic fatigue, and other serious health issues. Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase.
52 
Stroke Journal
FEBRUARY 1, 2024
Regarding comorbidities, congestive heart failure (OR 1.73, p <0.01, CI 1.32 Regarding comorbidities, congestive heart failure (OR 1.73, p <0.01, CI 1.32 to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27 to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
40 
AMS Cardiology
AUGUST 15, 2023
It damages blood vessels, decreases oxygen to the heart and raises the risk of heart disease. Obesity and poor diet – Being overweight coupled with other risk factors can lead to heart problems. Heart issues can encompass a wide range of problems, from coronary artery disease to heart failure, arrhythmias and more.
Stroke Journal
JANUARY 30, 2025
In unadjusted analysis, factors significantly associated with troponin testing were a triage complaint of chest pain, older age, higher mean systolic BP, hypertension, diabetes, obesity, stroke or TIA, congestive heart failure, or coronary disease.
40 
Stroke Journal
FEBRUARY 1, 2024
VRFs included hypertension, dyslipidemia, obesity, smoking, atrial fibrillation, coronary artery disease, heart failure, diabetes, and sleep apnea. Patients aged 18-55 with a diagnosis of IS were included and separated into two age groups: 18-35 and 36-55.
40 
DAIC
DECEMBER 8, 2023
If untreated, AFib can lead to or exacerbate heart failure, and it significantly increases a person’s risk of stroke. Catheter ablation was given the highest Class 1 treatment recommendation for appropriately selected patients, including those with heart failure with reduced ejection fraction.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content